First look: how a new Weight-Loss drug handles by the Body's kidneys
NCT ID NCT07429045
Summary
This early-stage study aimed to understand how a single dose of an experimental drug called AMG 133, being developed for overweight and obesity, is processed by the body in people with normal and impaired kidney function. It involved 44 adults to measure the drug's levels in the blood and check for safety. The goal was to gather basic information on how kidney health affects this potential treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AdvancedPharma CR LLC
Miami, Florida, 33147-4040, United States
-
Floridian Clinical Research, LLC
Miami Lakes, Florida, 33016, United States
-
Omega Research Group, LLC - Orlando
Orlando, Florida, 32806-1133, United States
-
Orange County Research Center
Lake Forest, California, 92630, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809-3017, United States
Conditions
Explore the condition pages connected to this study.